Wednesday , December 13 2017
Home / Therapies / SGLT-2 Therapy Center (page 17)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Obesity 2014, Part 7

DCMS180HS

Dr. Stanley Schwartz finishes up his slides series on the current state of the obesity epidemic and its relationship with diabetes. Topics covered in this set include a discussion of the newest drug therapies on the market including the incretins and the SGLT-2 inhibitors…. To download in PowerPoint (.ppt) format: Obesity …

Read More »

FDA Puts Empagliflozin on Hold

Quality issues in the manufacturing plant prevents final approval…. The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week. Eli Lilly and Boehringer Ingelheim said the FDA had issued a complete response …

Read More »

Ipragliflozin and HbA1C Levels

How does SGLT-2 inhibitor, ipragliflozon compare to metformin alone?…. Ipragliflozin is an oral medication in development by Astellas Pharma for the treatment of type 2 diabetes. A novel selective sodium glucose co-transporter-2 (SGLT-2) inhibitor, ipragliflozin works similarly to the first in class marketed SGLT-2 inhibitor drug, canagliflozin, by increasing urinary …

Read More »

Treatment with Ipragliflozin + Metformin

Combination well-tolerated in patients with type 2 diabetes…. Ipragliflozin is an oral medication in development by Astellas Pharma for the treatment of type 2 diabetes. A novel selective sodium glucose co-transporter-2 (SGLT-2) inhibitor, ipragliflozin works similarly to the first in class marketed SGLT-2 inhibitor drug canagliflozin by increasing urinary excretion …

Read More »

History of the SGLT2 Inhibitor Drug Class

Phuong Nguyen, PharmD Candidate, LECOM College of Pharmacy Remarkable as it might sound, the SGLT2 inhibitor drug class arguably dates back 178 years. In 1835, French chemists first isolated a substance known as phlorizin from the bark of apple trees, and in 1886, German physician and early diabetes pioneer Joseph von …

Read More »

The Expansion of the SGLT-2 Inhibitor Market

What’s New on the Horizon? Heather Good, Doctor of Pharmacy, Candidate University of Florida Sodium-glucose co-transporter 2 (SGLT2) inhibitors, the first drugs to actually eliminate glucose from the body, are paving the way for a new wave of diabetes treatment options. Canagliflozin (Invokana®) took the U.S. market by storm when …

Read More »